Current Tropical Medicine Reports

, Volume 5, Issue 1, pp 24–30 | Cite as

Prevention and Treatment of Pediatric HIV Infection

  • Philippa Musoke
  • Zikulah Namukwaya
  • Linda Barlow Mosha
Pediatric Global Health (D Nguyen and A Mandalakas, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Pediatric Global Health


Purpose of Review

The goal of this paper is to review the prevention of mother-to-child HIV transmission (PMTCT) research that informed World Health Organization (WHO) guidelines for PMTCT and describe the impact of worldwide scale-up of PMTCT programs and antiretroviral therapy (ART) coverage. The impact of these interventions on new pediatric infections and infected children’s morbidity and mortality in sub-Saharan Africa are reviewed.

Recent Findings

The IMPAACT PROMISE study demonstrated that triple therapy consisting of tenofovir (TDF), lamivudine (3TC), and lopinavir/ritonavir (LPVr) or zidovudine (AZT), 3TC, and LPVr initiated in the first trimester reduced vertical transmission at 2 weeks of age to 0.6% and 0.5%, respectively, supporting the current WHO Option B+ recommendation for PMTCT. However, increased adverse pregnancy outcomes in the AZT- and TDF-based triple therapy arms were reported when compared with the AZT prophylaxis arm (low birth weight [20.4% and 16.9% vs. 8.9%; p = 0.004] and premature deliveries [19.7% and 18.5% vs. 13.5%; p = 0.09], respectively). Implementation of Option B+ for PMTCT has led to significant reductions in vertical transmission rates, including elimination of new pediatric infections in some countries. The WHO declared elimination of mother-to-child HIV transmission (MTCT) in Cuba in 2015 and in Armenia, Belarus, and Thailand in 2016.


Globally, new pediatric HIV infections have declined significantly since the introduction of effective antiretroviral regimens for PMTCT. Perinatal HIV prevention clinical trials conducted in sub-Saharan Africa informed WHO PMTCT guidelines which led to implementation of PMTCT programs worldwide, leading to a 47% reduction in new pediatric infections since 2009. Support from The United States President's Emergency Plan for AIDS Relief (PEPFAR), the Global Fund for AIDS, Tuberculosis and Malaria, and UN agencies has enabled scale-up of national PMTCT programs, and increased antiretroviral coverage (47% globally) for infected children has led to a decline in HIV/AIDS-related mortality in children. Implementation strategies that improve retention in care and adherence to ART in pregnant and breastfeeding HIV-infected women is critical to ensure that more countries achieve the elimination of MTCT (eMTCT) targets. Assessing the effectiveness of new antiretroviral drugs, including fixed-dose combinations and long-acting formulations, is key to improving ART adherence and reducing the emergence of viral resistance mutations. In addition, interventions to prevent HIV transmission in adolescents and young adults is critical for reducing new HIV infections worldwide. Innovative interventions to improve adherence to ART are required to further improve the survival of HIV-infected children and adolescents.


HIV-infected children Prevention of HIV Pediatric antiretroviral treatment eMTCT Child mortality Sub-Saharan Africa 


Compliance with Ethical Standards

Conflict of Interest

Philippa Musoke, Zikulah Namukwaya, and Linda Barlow Mosha declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    UNAIDS. UNAIDS report 2016. Geneva: UNAIDS; 2016.Google Scholar
  2. 2.
    UNAIDS. Start Free, Stay Free, AIDS Free. A super-fast-track framework for ending AIDS Among Children, Adolescents And Young Women By 2020. Geneva: UNAIDS 2016Google Scholar
  3. 3.
    Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359(9313):1178–86.CrossRefGoogle Scholar
  4. 4.
    Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet. 1999;353(9155):786–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795–802.CrossRefPubMedGoogle Scholar
  6. 6.
    Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343(14):982–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353(9155):773–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet. 1999;353(9155):781–5.CrossRefPubMedGoogle Scholar
  9. 9.
    UNAIDS PaP. Start Free, Stay Free, AIDS Free: A super fast track framework for ending AIDS among children, adolescents and young women by 2020’. 2016.Google Scholar
  10. 10.
    Nduati R. Breastfeeding and HIV-1 infection. A review of current literature. Adv Exp Med Biol. 2000;478:201–10.CrossRefPubMedGoogle Scholar
  11. 11.
    UNAIDS. 2015 Progress report on the global plan. 2015. Accessed 22 Jan 2018.
  12. 12.
    WHO. Progress report 2016: prevent HIV, test and treat all - WHO support for country impact. Geneva: WHO; 2016.Google Scholar
  13. 13.
    WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016.Google Scholar
  14. 14.
    WHO. Health for the world’s adolescents: a second chance in the second decade. Geneva: WHO; 2014.Google Scholar
  15. 15.
    United Nations. Declaration of commitment on HIV/AIDS. United Nations General Assembly Special Session on HIV/AIDS; 25–27 Jun 2001; Geneva.Google Scholar
  16. 16.
    Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Aizire J, Fowler MG, Coovadia HM. Operational issues and barriers to implementation of prevention of mother-to-child transmission of HIV (PMTCT) interventions in Sub-Saharan Africa. Curr HIV Res. 2013;11(2):144–59.CrossRefPubMedGoogle Scholar
  18. 18.
    Chi BH, Adler MR, Bolu O, Mbori-Ngacha D, Ekouevi DK, Gieselman A, et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr. 2012;60(Suppl 3):S78–87.CrossRefPubMedGoogle Scholar
  19. 19.
    du Plessis E, Shaw SY, Gichuhi M, Gelmon L, Estambale BB, Lester R, et al. Prevention of mother-to-child transmission of HIV in Kenya: challenges to implementation. BMC Health Serv Res. 2014;14(Suppl 1):S10.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Paintsil E, Andiman WA. Update on successes and challenges regarding mother-to-child transmission of HIV. Curr Opin Pediatr. 2009;21(1):94–101.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fowler MG, Coovadia H, Herron CM, Maldonado Y, Chipato T, Moodley D, et al. HPTN 046 Protocol Team. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014;65(3):366–74.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet. 2012;379(9835):2449–58.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171–80.CrossRefGoogle Scholar
  24. 24.
    Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726–37.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    WHO. In: WHO, editor. Prevention of mother to child transmission of HIV: selection and use of nevirapine - technical notes. Geneva; 2001.Google Scholar
  26. 26.
    WHO. Saving mothers, saving families: the MTCT-Plus Initiative. Perspectives and practice in antiretroviral treatment. Case study. Geneva: WHO; 2003.Google Scholar
  27. 27.
    WHO. AIDS epidemic update: 2003. Geneva: WHO; 2003.Google Scholar
  28. 28.
    WHO. Abuja PMTCT Call to Action: towards an HIV-free and AIDS-free generation. Abuja: Prevention of Mother to Child Transmission (PMTCT) High Level Global Partners Forum; 2005.Google Scholar
  29. 29.
    WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2016.Google Scholar
  30. 30.
    UNICEF. Towards universal access: scaling up HIV services for women and children in the health sector–progress report 2008. New York: UNICEF; 2008.Google Scholar
  31. 31.
    WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach-2010 version. Geneva: World Health Organization; 2010.Google Scholar
  32. 32.
    WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents-November 2009. Geneva: WHO; 2009.Google Scholar
  33. 33.
    WHO. Guidelines on HIV and infant feeding. Principles and recommendations for infant feeding in the context of HIV and a summary of evidence. Geneva: WHO; 2010.Google Scholar
  34. 34.
    WHO. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: programatic update. Geneva: WHO; 2012.Google Scholar
  35. 35.
    UNAIDS. Fact sheet - latest statistics on the status of the AIDS epidemic. Geneva: UNAIDS; 2016.Google Scholar
  36. 36.
    Myer L, Phillips TK. Beyond "Option B+": understanding antiretroviral therapy (ART) adherence, retention in care and engagement in ART services among pregnant and postpartum women initiating therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2017;75(Suppl 2):S115–22.CrossRefPubMedGoogle Scholar
  37. 37.
    Besada D, Rohde S, Goga A, Raphaely N, Daviaud E, Ramokolo V, et al. Strategies to improve male involvement in PMTCT Option B+ in four African countries: a qualitative rapid appraisal. Glob Health Action. 2016;9:33507.CrossRefPubMedGoogle Scholar
  38. 38.
    Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2013;16:18588.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One. 2012;7(2):e28510.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Little K, Thorne C, Luo C, Bunders M, Ngongo N, McDermott P, et al. Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment. Curr HIV Res. 2007;5(2):139–53.CrossRefPubMedGoogle Scholar
  41. 41.
    Modi S, Chiu A, Ng'eno B, Kellerman SE, Sugandhi N, Muhe L. Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings. AIDS. 2013;27(Suppl 2):S159–67.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–44.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: Switzerland; 2015.Google Scholar
  44. 44.
    Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, Siberry G, et al. Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. J Int AIDS Soc. 2017;20(1):21552.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev. 2012;7:CD004772.Google Scholar
  46. 46.
    L-B MR, Drouin O, Bartlett G, Nguyen Q, Low A, Gavriilidis G, et al. Incidence and prevalence of opportunistic and other infections and the impact of antiretroviral therapy among HIV-infected children in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(12):1586–94.CrossRefGoogle Scholar
  47. 47.
    Peacock-Villada E, Richardson BA, John-Stewart GC. Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics. 2011;127(2):e423–41.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381(9875):1391–403.CrossRefPubMedGoogle Scholar
  49. 49.
    Penazzato M, Palladino C, Sugandhi N. Prioritizing the most needed formulations to accelerate paediatric antiretroviral therapy scale-up. Curr Opin HIV AIDS. 2017;12(4):369–76.CrossRefPubMedGoogle Scholar
  50. 50.
    Ferrand RA, Briggs D, Ferguson J, Penazzato M, Armstrong A, MacPherson P, et al. Viral suppression in adolescents on antiretroviral treatment: review of the literature and critical appraisal of methodological challenges. Tropical Med Int Health. 2016;21(3):325–33.CrossRefGoogle Scholar
  51. 51.
    Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS. 2014;28(13):1945–56.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, Viola V, Mutabazi V, Alwar T, et al. High attrition before and after ART initiation among youth (15-24 years of age) enrolled in HIV care. AIDS. 2014;28(4):559–68.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Murray KR, Dulli LS, Ridgeway K, Dal Santo L, Darrow de Mora D, Olsen P, et al. Improving retention in HIV care among adolescents and adults in low- and middle-income countries: a systematic review of the literature. PLoS One. 2017;12(9):e0184879.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    WHO, CIPHER, IAS. A global research agenda for adolescents living with HIV Research for an AIDS free generation. WHO/HIV/2017.33. Geneva: WHO; 2017.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Philippa Musoke
    • 1
    • 2
  • Zikulah Namukwaya
    • 2
  • Linda Barlow Mosha
    • 2
  1. 1.Department of Paediatrics and Child HealthMakerere UniversityKampalaUganda
  2. 2.Makerere University-Johns Hopkins University Research CollaborationKampalaUganda

Personalised recommendations